Hylant aims to help clients substantially reduce large claim costs without disrupting medical treatments.
A manufacturer’s medical costs increased more than one million dollars within 12 months. Hylant reviewed the company’s self-funded medical program and discovered the company had two medical plan participants with hemophilia, a genetic blood disorder that requires expensive treatment. The client needed a strategy to manage their cost of care without disrupting medical treatment.
What We Did
Download the case study to see how Hylant partnered with the Hemophilia Alliance to provide cost containment, drastic savings and ensured participants didn’t have their care disrupted.